singl
amino
acid
substitut
histidin
tyrosin
posit
neuraminidas
gene
convert
oseltamivir
sensit
influenza
viru
resist
strain
current
oseltamivir
stockpil
mani
countri
potenti
affect
influenza
viru
subtyp
epidem
identifi
chang
oseltamivirtr
patient
method
base
realtim
pcr
use
two
label
taqman
probe
develop
rapid
detect
order
valid
method
oseltamivir
specimen
treat
oseltamivirresist
strain
vietnames
patient
two
oseltamivirtr
tiger
untreat
subject
use
studi
result
thu
obtain
well
deriv
clone
select
sequenc
show
taqman
probe
could
clearli
discrimin
wild
type
mutant
variant
sensit
assay
low
copiesl
allow
detect
mutat
mixtur
wild
type
mutant
overal
assay
base
realtim
pcr
two
label
taqman
probe
describ
use
detect
oseltamivirresist
influenza
viru
mani
speci
variou
sourc
specimen
high
sensit
specif
studi
address
potenti
differ
diagnost
outcom
patient
develop
detect
oseltamivir
resist
retain
wild
type
strain
influenza
viru
rna
viru
orthomyxovirida
famili
annual
influenza
virus
may
develop
symptomat
influenza
children
adult
worldwid
turner
et
al
three
type
ac
b
caus
widespread
outbreak
subtyp
influenza
viru
base
antigen
differ
two
surfac
glycoprotein
haemagglutinin
ha
neuraminidas
na
nowaday
ha
na
subtyp
describ
fouchier
et
al
nicholson
et
al
sinc
influenza
viru
subtyp
caus
sever
diseas
variou
poultri
mammal
clinic
spectrum
avian
influenza
human
compris
initi
symptom
high
fever
exceed
c
lower
respiratori
tract
symptom
clinic
signific
lymphopenia
abnorm
chest
radiographi
case
diarrhea
vomit
tran
et
al
enceph
overal
fatal
rate
among
hospit
patient
avian
influenza
infect
amount
two
group
antivir
agent
current
avail
treatment
influenza
infect
adamantan
amantadin
rimantadin
block
function
protein
howev
drug
resist
patient
increas
hayden
hay
recent
develop
class
viral
neuraminidas
inhibitor
includ
zanamivir
relenza
oseltamivir
tamiflu
import
antivir
medic
use
strain
influenza
viru
oseltamivir
first
oral
activ
neuraminidas
inhibitor
form
capsul
powder
liquid
suspens
kim
et
al
neuraminidas
inhibitor
nai
oseltamivir
imit
natur
neuraminidas
substrat
molecul
bind
activ
site
enzym
addit
interf
releas
progeni
influenza
viru
infect
host
cell
moscona
therefor
neuraminidas
na
cleav
termin
nacetylneuramin
acid
residu
oligosaccharid
chain
thu
virion
selfaggreg
bind
surfac
infect
cell
oseltamivir
resist
due
neuraminidas
mutat
arisen
challeng
studi
patient
natur
acquir
infect
rate
resist
estim
around
adult
popul
pediatr
patient
jackson
et
al
whitley
et
al
kiso
et
al
analyz
influenza
virus
collect
children
treatment
oseltamivir
eighteen
percent
children
n
neuraminidas
mutat
n
n
n
volunt
experiment
infect
influenza
viru
treat
oseltamivir
shown
substitut
neuraminidas
activ
site
gubareva
et
al
mutat
respons
oseltamivir
phosphat
treatment
leav
viru
sever
compromis
vitro
vivo
ive
et
al
confer
resist
wetheral
et
al
mutat
posit
influenc
sensit
influenza
na
yet
na
oseltamivir
carboxyl
rearrang
shape
activ
site
creat
pocket
oseltamivir
gubareva
moscona
wang
et
al
safeguard
potenti
influenza
viru
subtyp
epidem
mani
countri
stockpil
oseltamivir
recent
report
oseltamivirresist
influenza
virus
mutat
isol
three
patient
virus
pronounc
oseltamivir
resist
isol
two
eight
vietnames
patient
oseltamivir
treatment
patient
die
januari
anoth
resist
case
die
februari
beigel
et
al
de
jong
et
al
le
et
al
increas
oseltamivirresist
virus
seem
like
method
aim
rapidli
identifi
resist
strain
appli
realtim
pcr
use
taqman
probe
design
assay
enabl
identifi
mutat
sampl
origin
directli
infect
tissu
plasma
oseltamivirtr
nontreat
specimen
sever
speci
infect
avian
influenza
subtyp
previous
detect
use
method
describ
payungporn
et
al
use
oseltamivirtr
specimen
oseltamivirresist
strain
vietnames
patient
n
oseltamivirtr
tiger
panthera
tigri
tigri
n
white
tiger
p
tigri
tigri
n
oseltamivir
untreat
specimen
plasma
infect
human
n
chutinimitkul
et
al
sever
tissu
differ
organ
tiger
lung
n
spleen
n
kidney
n
liver
n
brain
leopard
panthera
pardu
n
allanto
fluid
embryon
chicken
egg
inocul
viru
accord
method
describ
offic
intern
de
epizooti
oie
origin
cat
feli
catu
n
dog
cani
familiari
n
quail
n
ostrich
n
chicken
n
specimen
isol
provid
faculti
veterinari
scienc
chulalongkorn
univers
bangkok
thailand
depart
livestock
develop
bangkok
thailand
faculti
veterinari
scienc
kasetsart
univers
kampaengsaen
campu
nakorn
pathom
thailand
depart
pediatr
faculti
medicin
srinakharinwirot
univers
nakhon
nayok
thailand
nation
institut
hygien
epidemiolog
hanoi
vietnam
nucleotid
sequenc
n
neuraminidas
gene
influenza
viru
taken
genbank
databas
go
back
far
henc
compris
entri
isol
variou
speci
avian
cat
dog
tiger
swine
human
includ
sequenc
one
vietnames
oseltamivirresist
patient
align
perform
use
clustal
x
version
ftp
ftpigbmcustrasbgfrpubclustalx
bioedit
sequenc
align
softwar
version
http
wwwmbioncsuedu
bioeditbioedithtml
assay
target
region
first
identifi
visual
inspect
sequenc
align
primer
chosen
constant
region
sequenc
specif
neuraminidas
gene
influenza
viru
close
relat
probe
mgb
taqman
probe
chosen
region
cover
drug
resist
area
design
specif
wild
type
mutant
primer
probe
analyz
use
primer
design
softwar
oligo
version
ruslan
kalendar
institut
biotechnolog
univers
helsinki
finland
primer
express
softwar
version
appli
biosystem
ca
wild
type
h
mutant
mgb
taqman
probe
label
fam
vic
emiss
wavelength
nm
respect
primer
probe
use
studi
shown
tabl
rna
sampl
extract
embryon
chicken
egg
previous
identifi
influenza
viru
subtyp
appli
design
seri
mutagenesi
oligonucleotid
depict
tabl
use
gener
seri
mutagenesi
amino
acid
posit
neuraminidas
gene
serv
control
possibl
pattern
nucleotid
chang
area
probe
bind
primer
serv
outer
primer
mutagenesi
group
pair
mutagenesi
primer
mutagenesi
primer
group
mutagenesi
primer
group
mutagenesi
primer
group
design
possibl
vari
strain
occasion
found
mutagenesi
product
group
use
construct
mutagenesi
group
mutagenesi
group
mutagenesi
group
primari
mutagenesi
pcr
reaction
mixtur
compris
l
cdna
forward
primer
outer
mutagenesi
primer
revers
primer
outer
mutagenesi
primer
l
mastermix
eppendorf
hamburg
germani
nucleasefre
water
final
volum
l
secondari
mutagenesi
pcr
reaction
mixtur
compris
l
pcr
product
repres
mutagenesi
group
l
mastermix
eppendorf
nucleasefre
water
final
volum
l
amplif
reaction
perform
mastercycl
person
eppendorf
follow
condit
predenatur
c
min
follow
amplif
cycl
consist
denatur
c
anneal
c
min
extens
c
conclud
final
min
extens
c
four
group
mutagenesi
pcr
product
separ
agaros
gel
electrophoresi
purifi
use
gel
extract
kit
perfectprep
gel
cleanup
eppendorf
hamburg
germani
purifi
product
insert
pgemt
easi
vector
system
promega
madison
wi
plasmid
purifi
use
high
pure
plasmid
isol
kit
roch
gmbh
germani
accord
manufactur
specif
seri
mutat
sequenc
use
control
viral
rna
extract
l
sampl
allanto
fluid
inocul
embryon
egg
plasma
supernat
result
tissu
extract
use
qiamp
viral
rna
mini
kit
qiagen
gmbh
germani
accord
manufactur
specif
revers
transcript
perform
l
rna
sampl
c
h
use
unit
mmlv
reversetrancriptas
promega
l
mmlv
reaction
buffer
promega
l
mm
dntp
promega
unit
rrnasin
ribonucleas
inhibitor
promega
univers
primer
describ
hoffmann
et
al
twelv
microlit
rna
rna
extract
kit
heat
c
min
cool
ice
ad
nucleasefre
water
final
volum
l
realtim
pcr
perform
use
biotool
quantimix
easi
probe
kit
biotool
madrid
spain
probe
primer
pair
depict
tabl
use
multipl
format
primer
probe
final
concentr
respect
combin
l
cdna
embryon
egg
l
cdna
tissu
serum
plasma
reaction
mixtur
contain
l
quantiprob
mm
mgcl
nucleasefre
water
adjust
final
volum
l
realtim
pcr
amplif
carri
rotorgen
instrument
corbett
research
sydney
australia
amplif
reaction
consist
preincub
step
c
min
activ
hotstartaq
dna
polymeras
follow
cycl
amplif
includ
denatur
c
anneal
c
extens
c
two
fluoresc
signal
obtain
per
cycl
end
extens
step
detector
correspond
fam
nm
vic
nm
channel
respect
data
acquisit
analysi
realtim
pcr
assay
perform
use
rotorgen
data
analysi
softwar
version
corbett
research
support
program
cdna
amplifi
pcr
reaction
mixtur
contain
l
mastermix
eppendorf
primer
f
primer
r
nucleasefre
water
final
volum
l
amplif
reaction
perform
mastercycl
person
eppendorf
follow
condit
predenatur
c
min
follow
amplif
cycl
compris
denatur
c
anneal
c
extens
c
conclud
final
extens
c
min
pcr
product
separ
agaros
gel
electrophoresi
purifi
use
gel
extract
kit
perfectprep
gel
cleanup
eppendorf
hamburg
purifi
product
insert
pgemt
easi
vector
system
promega
accord
manufactur
protocol
ten
clone
randomli
select
result
white
coloni
plasmid
purifi
use
high
pure
plasmid
isol
kit
roch
gmbh
accord
manufactur
specif
autom
dna
sequenc
plasmid
amplifi
use
gene
amp
pcr
system
perkinelm
sequenc
product
subject
perkinelm
sequenc
analyz
perkinelm
specif
dual
probe
realtim
pcr
evalu
crossreact
test
carri
rna
extract
isol
clinic
specimen
express
entir
spectrum
na
subtyp
refer
strain
influenza
viral
pathogen
newcastl
diseas
viru
ndv
respiratori
syncyti
viru
rsv
subgroup
b
human
metapneumoviru
hmpv
coronaviru
coronaviru
infecti
bursal
diseas
viru
ibdv
infecti
bronchiti
viru
ibv
sensit
establish
plasmid
contain
copi
wild
type
mutant
serv
refer
wild
type
mutant
plasmid
use
determin
capac
realtim
pcr
assay
detect
wild
type
oseltamivirresist
codon
mutant
singl
sampl
dna
concentr
determin
measur
absorb
nm
two
control
plasmid
dilut
copiesl
result
concentr
mix
wild
typetovari
ratio
realtim
pcr
analysi
potenti
codon
variant
perform
ratio
concentr
condit
describ
result
obtain
use
two
taqman
probe
label
fam
vic
fluoresc
signal
wild
type
mutant
detect
respect
fluoresc
signal
result
realtim
pcr
interpret
shown
fig
sampl
contain
wild
type
strain
emit
fluoresc
signal
exclus
via
fam
channel
nm
wherea
sampl
contain
oseltamivirresist
variant
nucleotid
alter
posit
neuraminidas
gene
emit
oseltamivirtr
vietnames
patient
le
et
al
show
fluoresc
signal
indic
combin
wild
type
resist
strain
oseltamivirtr
white
tiger
oseltamivirtr
tiger
show
wild
type
signal
fluoresc
signal
via
vic
channel
nm
order
develop
optim
assay
probe
test
four
set
mutagenesi
obtain
clearli
discern
result
irrespect
concentr
wild
type
mutant
plasmid
ratio
mix
clinic
sampl
test
assay
isol
human
tiger
leopard
cat
dog
variou
avian
speci
previous
infect
two
human
specimen
experi
investig
first
one
isol
human
plasma
collect
nakhonnayok
provinc
show
posit
result
wild
type
contrast
second
one
obtain
vietnames
patient
previous
report
le
et
al
emit
signal
specif
wild
type
mutant
remain
specimen
origin
tiger
lung
spleen
kidney
liver
leopard
brain
allanto
fluid
variou
avian
speci
cat
dog
display
posit
result
specif
wild
type
three
specimen
treat
oseltamivir
chosen
clone
plasmid
confirm
first
specimen
tiger
isol
zoo
tiger
perish
midoctob
influenza
outbreak
isol
nasal
swab
tiger
eventu
perish
treat
oseltamivir
kg
twice
daili
day
prior
specimen
collect
amonsin
et
al
thanawongnuwech
et
al
inocul
sanfowl
egg
accord
method
describ
offic
intern
de
epizooti
oie
ten
clone
randomli
select
sequenc
clone
sensit
oseltamivir
second
specimen
white
tiger
isol
sick
white
tiger
found
posit
nasal
swab
subsequ
treat
oseltamivir
kg
twice
daili
day
tiger
surviv
rectal
swab
taken
specimen
inocul
sanfowl
egg
ten
clone
randomli
select
sequenc
clone
sensit
oseltamivir
third
specimen
cdna
vietnames
patient
le
et
al
ten
clone
strain
randomli
select
sequenc
nine
clone
resist
oseltamivir
clone
sensit
specif
assay
crosscontamin
test
evalu
found
crossreact
total
human
dna
differ
na
subtyp
influenza
viru
newcastl
diseas
viru
ndv
respiratori
syncyti
viru
rsv
subgroup
b
human
metapneumoviru
hmpv
coronaviru
coronaviru
infecti
bursal
diseas
viru
ibdv
infecti
bronchiti
viru
ibv
likewis
signific
fals
posit
nonspecif
signal
sampl
test
observ
overal
result
obtain
oseltamivir
resist
two
label
probe
indic
high
specif
primer
probe
use
amplif
sensit
realtim
pcr
threshold
concentr
detect
wild
type
mutant
copiesl
furthermor
order
establish
limit
realtim
pcr
detect
wild
type
mutant
sampl
wild
type
mutant
plasmid
mix
variou
ratio
dilut
rang
concentr
ratio
wild
type
mutant
result
show
high
sensit
detect
detect
although
reaction
plasmid
copiesl
wild
type
mutant
present
substanti
risk
global
influenza
viru
subtyp
epidem
affect
poultri
also
mammalian
speci
includ
human
medic
capabl
prevent
spread
human
neuraminidas
inhibitor
oseltamivir
yet
influenza
viru
subtyp
alreadi
develop
drug
resist
mutat
neuraminidas
gene
lead
amino
acid
substitut
predominantli
posit
number
system
enzym
activ
site
gubareva
et
al
amino
acid
substitut
posit
identifi
mutant
select
presenc
na
inhibitor
vivo
vitro
exclus
found
gubareva
et
al
viru
resist
oseltamivir
due
amino
acid
chang
histidin
h
tyrosin
base
singl
nucleotid
alter
posit
isol
three
vietnames
patient
one
year
old
recov
le
et
al
remain
two
year
old
succumb
infect
de
jong
et
al
henc
patient
found
posit
infect
ought
monitor
nucleotid
chang
posit
caus
resist
oseltamivir
onset
treatment
mutat
detect
time
altern
treatment
appli
exampl
zanamivir
might
save
patient
life
experi
probe
primer
specif
design
detect
nucleotid
chang
caus
oseltamivir
resist
amino
acid
substitut
histidin
h
tyrosin
consequ
singl
nucleotid
first
codon
amino
acid
chang
c
align
neuraminidas
gene
sequenc
sequenc
store
genbank
databas
show
nucleotid
chang
specif
probe
area
yet
posit
trigger
critic
amino
acid
alter
henc
probe
design
allow
inconsequenti
mutat
use
degener
nucleotid
posit
thu
close
mimick
natur
situat
moreov
sinc
conserv
area
gene
restrict
probe
length
nucleotid
taqman
mgb
chosen
probe
coupl
minor
groov
binder
enhanc
tm
nonfluoresc
quencher
attach
end
interfer
fluoresc
signal
detect
test
probe
mutagenesi
control
result
show
high
sensit
correct
distinct
wild
type
mutant
upon
mix
differ
ratio
wild
type
mutant
plasmid
low
concentr
conclus
realtim
pcr
use
two
label
taqman
probe
provid
highli
specif
sensit
method
detect
amino
acid
alter
posit
influenza
subtyp
neuraminidas
gene
caus
oseltamivir
resist
studi
one
describ
could
address
potenti
differ
diagnost
outcom
patient
develop
detect
oseltamivir
resist
patient
retain
wild
type
strain
howev
point
mutat
oseltamivir
resist
infect
mammalian
speci
need
investig
